Since the offering is being made at a lower valuation than the current book value, KDventures will – in accordance with its internal valuation policies – reduce the book value of the holding by 65.5 percent, equivalent to SEK 390.1 million, compared with the portfolio value of March 31, 2026. The new, pre-money book value is based on calculations by an independent third-party valuer, considering the terms of the new share issue. The write-down has no impact on KDventures’ cash flow and will be reported in the second quarter report. KDventures’ net asset value per share will decrease by 35.2 percent, pre-money, equivalent to SEK 0.59 per share. The net asset value per share amounts to SEK 1.09, after the write-down and subsequent investments.

"We welcome the participation of both new and existing investors in Umecrine Cognition’s capital raise. The company is approaching key readouts from the ongoing phase 1b/2a study with golexanolone. While the financing does result in a write-down of the portfolio company's book value, it does not change our confidence in the company, which is why KDventures is participating in the offering with at least SEK 24.5 million, of which SEK 10 million relates to a set-off against a convertible loan from Q4 2025,” says Viktor Drvota, CEO of KDventures and Umecrine Cognition.

“The write-down of Umecrine Cognition’s book value is unfortunate, but KDventures’ board and management believe it is essential that our balance sheet accurately reflects the value of our portfolio companies. By prioritizing transparency and accurate asset valuation, we are laying the groundwork for increased shareholder value,” comments Anders Hallberg, KDventures’ Chairman of the Board.

Read more about Umecrine Cognition, the ongoing study and the capital raise in an interview with CEO Viktor Drvota which will be published shortly on KDventures’ investor platform: https://ir.kd-ventures.com/en

About Umecrine Cognition

Umecrine Cognition is developing golexanolone, a drug candidate that acts on the central nervous system to alleviate fatigue and cognitive symptoms in chronic liver disease. Patient enrollment is currently underway at more than 30 European clinical sites, and results from the study are expected to be presented in the second half of 2026.